Retatrutide is one of the most closely watched next-generation weight management drugs currently in development. Often described as a “triple agonist”, it is designed to activate three hormone receptors involved in appetite, blood sugar regulation and energy balance: GIP, GLP-1 and glucagon.
Unlike single GLP-1 medicines, retatrutide aims to work across multiple metabolic pathways at once. This has made it a major focus in clinical research for obesity, overweight, type 2 diabetes and obesity-related complications such as knee osteoarthritis and obstructive sleep apnoea.
At the time of writing, retatrutide remains an investigational medicine. That means it has shown strong clinical trial results, but it is not yet an approved treatment for general medical use. Its progress so far, however, has been significant.
What Is Retatrutide?
Retatrutide, also known by its development code LY3437943, is a once-weekly injectable medicine being developed by Eli Lilly. It belongs to a newer class of metabolic medicines that target more than one hormone receptor.
Retatrutide activates:
-
GIP receptors, which are involved in insulin response and metabolic regulation
-
GLP-1 receptors, which help regulate appetite, satiety and blood glucose
-
Glucagon receptors, which may influence energy expenditure and fat metabolism
This triple-action approach is what separates retatrutide from older GLP-1-only medicines and even from dual agonists such as tirzepatide.
Stage 1: Early Research and Phase 1 Trials
The first major step for retatrutide was early safety and proof-of-concept testing. Phase 1 trials are designed to assess safety, tolerability, dosing and how the drug behaves in the body.
In early studies, retatrutide showed a safety and tolerability profile broadly similar to other incretin-based therapies. Its pharmacokinetic profile also supported once-weekly dosing, which is important for patient convenience and long-term adherence.
These early results gave researchers enough confidence to move retatrutide into larger phase 2 studies, where its impact on body weight, blood sugar and metabolic health could be tested more fully.
Stage 2: Phase 2 Trial in Obesity and Overweight
Retatrutide gained major attention after its phase 2 obesity trial. This study looked at adults with obesity or overweight, but without type 2 diabetes. Participants received different once-weekly doses of retatrutide or placebo over 48 weeks.
The results were highly significant. Retatrutide met the primary endpoint at 24 weeks, with the highest doses producing substantial average weight reduction. By 48 weeks, participants receiving higher doses achieved even greater weight loss, with the top result reaching an average body weight reduction of up to 24.2%.
This was an important milestone because it showed that retatrutide could produce large, dose-dependent reductions in body weight over time. Another key point was that many participants had not yet reached a weight-loss plateau by the end of the trial, suggesting that longer studies could show further results.
The most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea and constipation. These were generally reported as mild to moderate and were most common during dose escalation.
Stage 3: Phase 2 Trial in Type 2 Diabetes
Retatrutide was also studied in people with type 2 diabetes. This was important because many people with type 2 diabetes also struggle with weight management, and effective treatments need to improve both blood sugar control and body weight.
In the phase 2 type 2 diabetes trial, retatrutide improved HbA1c and reduced body weight compared with placebo. Higher doses produced stronger weight-loss effects, while blood sugar markers also improved meaningfully.
This trial helped support the idea that retatrutide may have potential not only as an obesity treatment, but also as a therapy for people with type 2 diabetes who need both glycaemic control and weight reduction.
The phase 2 diabetes data also helped guide dose selection for later phase 3 trials.
Stage 4: Phase 3 Programme Begins
After successful phase 2 results, retatrutide moved into phase 3 clinical development. Phase 3 trials are larger, longer and designed to provide the kind of evidence regulators need when assessing whether a medicine should be approved.
Eli Lilly’s phase 3 programme for retatrutide includes studies across obesity, overweight, type 2 diabetes and obesity-related complications. These trials include the TRIUMPH and TRANSCEND programmes.
The key phase 3 areas include:
-
Obesity or overweight without diabetes
-
Obesity or overweight with type 2 diabetes
-
Obesity with knee osteoarthritis
-
Obesity with obstructive sleep apnoea
-
Obesity with cardiovascular disease
-
Longer-term metabolic and safety outcomes
Stage 5: Successful Phase 3 Trial in Obesity and Knee Osteoarthritis
One of the first major phase 3 wins for retatrutide came from the TRIUMPH-4 trial. This study looked at adults with obesity or overweight and knee osteoarthritis.
The trial met its co-primary endpoints, showing both significant weight loss and improvement in knee pain. At the highest dose, participants lost an average of 28.7% of body weight at 68 weeks. The study also showed major improvements in WOMAC pain scores, a standard measure used in osteoarthritis research.
This was especially important because obesity and knee osteoarthritis are closely linked. Excess body weight can increase mechanical stress on the joints, while inflammation and reduced mobility can make weight management more difficult. A treatment that improves both weight and pain outcomes could therefore be valuable for this patient group.
Stage 6: Successful Phase 3 Trial in Type 2 Diabetes
Retatrutide also met key goals in the TRANSCEND-T2D-1 phase 3 trial, which studied adults with type 2 diabetes.
In this trial, retatrutide produced significant reductions in HbA1c and body weight compared with placebo. Across tested doses, average HbA1c reductions reached up to 2.0%, while the highest dose produced average weight loss of up to 16.8% at 40 weeks.
This result strengthened retatrutide’s clinical profile in type 2 diabetes, particularly because weight loss is often harder to achieve in people with diabetes than in those without diabetes.
The most common adverse events were again gastrointestinal, including nausea, diarrhoea and vomiting, mostly occurring during dose escalation.
Stage 7: Successful Pivotal Phase 3 Trial in Obesity
A major milestone came with the TRIUMPH-1 phase 3 obesity trial. This trial studied adults with obesity or overweight and at least one weight-related comorbidity, but without diabetes.
Retatrutide met the primary and key secondary endpoints. At 80 weeks, participants taking 12 mg retatrutide lost an average of 28.3% of body weight. The 9 mg dose produced average weight loss of 25.9%, while the 4 mg dose produced average weight loss of 19.0%.
A particularly notable result was that 45.3% of participants on the 12 mg dose achieved at least 30% body weight reduction. In a pre-specified extension involving people with a baseline BMI of 35 or above, continued treatment produced average weight loss of up to 30.3% at 104 weeks.
These results placed retatrutide among the most powerful weight-loss medicines currently in late-stage development.
What Side Effects Have Been Reported?
Across retatrutide trials, the most common side effects have been similar to those seen with other incretin-based medicines. These include:
-
Nausea
-
Diarrhoea
-
Vomiting
-
Constipation
-
Reduced appetite
-
Gastrointestinal discomfort
Some phase 3 studies also reported dysesthesia, which refers to abnormal sensations such as tingling or altered skin sensation. In the available data, these events were generally mild to moderate, and many resolved during treatment.
As with any investigational drug, longer-term safety data is still important. Phase 3 trials and regulatory review are designed to assess whether the benefits outweigh the risks for specific patient groups.
Is Retatrutide Approved Yet?
No. Retatrutide has produced successful results in multiple clinical trial stages, but it remains investigational at the time of writing. It should not be used outside properly regulated clinical trials or prescribed medical settings.
The next major step is for the remaining phase 3 data to be completed, presented and reviewed by regulators. Only after regulatory approval could retatrutide become available as a licensed medicine.
Why Retatrutide Matters
Retatrutide is important because it represents a new direction in obesity and metabolic health treatment. Rather than targeting one pathway, it targets three hormone systems involved in appetite, glucose control and energy balance.
So far, it has successfully passed several major clinical milestones:
-
Phase 1 studies showed early safety, tolerability and once-weekly dosing potential.
-
Phase 2 obesity trials showed substantial weight loss in adults with obesity or overweight.
-
Phase 2 diabetes trials showed improvements in blood sugar control and body weight.
-
Phase 3 knee osteoarthritis data showed strong weight loss and pain improvement.
-
Phase 3 type 2 diabetes data showed significant HbA1c reduction and weight loss.
-
Phase 3 obesity data showed some of the strongest weight-loss results seen in modern obesity drug development.
Final Thoughts
Retatrutide has not yet reached the final stage of becoming an approved medicine, but it has successfully met several major clinical trial milestones. Its phase 2 and phase 3 results suggest it could become a significant future option for obesity, overweight, type 2 diabetes and certain obesity-related complications.
The strongest results so far have come from phase 3 obesity studies, where retatrutide produced average weight loss approaching 30% in some groups. However, it is still essential to wait for full trial publications, regulatory review and long-term safety assessment before drawing final conclusions.
For now, retatrutide is one of the most promising investigational medicines in metabolic health, but it remains a clinical trial drug rather than an approved treatment.